Beatrice's $1.65 billion acquisition and Polypide's commercialization steps
PYPD Polypid Ltd
$6.15 -1.76%
View chart & analysis → - 1Beatrice has finalized the $1.65 billion acquisition of Pasira Bioscience.
- 2D-PLEX100 confirmed a 60% reduction in the relative risk of surgical site infections compared to standard care.
- 3Polypide will partner with Azurity Pharmaceuticals to access more than 1,700 hospitals and academic centers in the US.
So what's the key point?
Beatrice has agreed to acquire Pasira Bioscience for $1.65 billion. This expands its business by securing technology that reduces post-surgical infections by 60%.
Source FinanceWire · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.